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Current sampling protocols of neoplasms along the digestive tract and in the urinary 
bladder have to be updated, as they do not respond to the necessities of modern 
personalized medicine. We show here that an adapted version of multisite tumor 
sampling (MSTS) is a sustainable model to overcome current deficiencies in digestive 
and bladder tumors when they are large enough so as to make unaffordable a total 
sampling. The new method is based on the divide-and-conquer algorithm and includes 
a slight modification of the MSTS, which proved to be useful very recently in clear cell 
renal cell carcinoma. This in silico analysis confirms the usefulness of MSTS for detecting 
intratumor heterogeneity (ITH) in tumors arising in hollow viscera. However, MSTS does 
not seem to improve routine traditional sampling in detecting tumor budding, extramural 
venous invasion, and perineural invasion. We conclude that (1) MSTS is the best method 
for tumor sampling to detect ITH balancing high performance and sustainable cost, (2) 
MSTS must be adapted to tumor shape and tumor location for an optimal performance.
Keywords: tumor sampling, intratumor heterogeneity, stomach, large bowel, urinary bladder, in silico modeling
iNtrODUctiON
Neoplasia has been proposed as a model of intracellular metabolic shift (1), where cells adopt an 
anaerobic glycolysis-dependent metabolism to sustain their uncontrolled proliferation, a phenom-
enon known as the Warburg effect (2). Molecular advances in the last years have revealed the extreme 
complexity of human tumors (3), and that intratumor heterogeneity (ITH) is a reflection of this 
complexity. ITH is obtaining an extraordinary importance in modern oncology during the last years 
(4, 5). Characteristically, ITH follows a stochastic spatial distribution along different tumor regions 
(6) making every single case really unique and unrepeatable. However, ITH is not a time-related 
tumor acquisition. In fact, a recent work has demonstrated in renal cancer that ITH appeared at 
very early stages in tumor development and therefore was not the result of tumor progression (7). 
Because ITH is high for most of the malignant tumors, it represents right now a major obstacle for 
the success of modern targeted therapies (8).
Many big tumors are in practice far away for being totally analyzed. In these situations, 
pathologists (the medical specialists handling surgical specimens and performing tumor 
samplings) partly sample such big tumors under the assumption that the selected samples are 
good representatives of the whole neoplasm. In other words, pathologists decide which parts 
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of the tumors will be selected for histological and molecular 
analysis and which parts will not (the latter ones usually cor-
respond with the tumor majority). For such a purpose, classic 
handling and routine sampling protocols (RP) are available 
for different tumor topographies in referential textbooks (9). 
However, these protocols were conceived in a dogmatic fashion 
during a period in which ITH was not a concerning issue 
and, surprisingly, none of them have been adapted to current 
necessities so far.
Recent literature shows many examples of controversial results 
(sometimes contradictory) in molecular analyses of the same 
tumor types and, even more important, deep disagreements in 
the performance of some expensive therapies. In this specific 
scenario, basic researchers, oncologists, and pathologists should 
first wonder how many of these apparent inconsistencies might 
be simply due to incomplete tumor samplings.
Representativeness of the tumor sample is an important 
issue in modern oncology, particularly in those cases in which 
therapeutic decisions are made with small core biopsies. In 
these cases, liquid biopsy appears in the next horizon as a 
promising alternative in detecting tumor heterogeneity and 
in identifying mutations associated with tumor aggressiveness. 
Furthermore, liquid biopsy could be regarded as a comple-
mentary sample to surgical specimens for the application of 
massive sequencing tools.
tHe cONteXt
An efficient sampling of a large tumor must ensure properly ITH 
detection without incurring extra costs, and such a method has 
not yet been established in modern pathology. We have recently 
suggested a novel method called multisite tumor sampling 
(MSTS) (10) that makes use of the same number of cassettes 
and obtain a much better performance in detecting ITH as 
compared to RP without extra costs. Importantly, MSTS was 
clinically validated for being more efficient in detecting ITH as 
compared to RP on a series of clear cell renal cell carcinomas 
(CCRCCs) (11).
Multisite tumor sampling is based on the divide-and-conquer 
(DAC) algorithm (12). DAC is a useful strategy to solve complex 
problems in basic science (13) and has been also applied to 
answer biological problems (14, 15). In short, the DAC strategy 
consists of recursively breaking down a problem into smaller 
parts (divide) until these are simple enough to be solved directly 
(conquer). Then, partial solutions are merged to solve the original 
problem.
Multisite tumor sampling was shown to be an efficient method 
to sample large tumors for neoplasms growing in solid organs, 
i.e., kidney (10). However, the same protocol can be applied to any 
other large tumors, like those arising in soft tissues, liver, lung, 
testis, thyroid, breast, and others.
Some carcinomas, however, do grow with different shapes in 
the mucosa (excavated, plaque-like, plateau-like, polypoid), not 
like simple spheroids, and their growth is different depending 
on the axis considered, i.e., vertical or horizontal. This tumor 
category is represented, for instance, by carcinomas along the 
digestive tract and in the urinary bladder.
tHe PrOBLeM
Gastric adenocarcinomas (GACs), colorectal adenocarcinomas 
(CRCs), and urothelial cell carcinomas (UCC) of the urinary 
bladder are substantially different neoplasms developing in 
similar topographic sites, since the digestive tract and the urinary 
bladder are hollow viscera with similar walls that include mucosa, 
submucosa, muscularis propria, and serosa. A significant subset 
of UCC and many GACs and CRCs are plaque-like shaped 
neoplasms having two main components of growth: superficial 
(radial spread) and vertical (deep invasion). Due to the specific 
characteristics of the local environment, it is likely that a substan-
tial part of the relevant information for these neoplasms such as 
biological aggressiveness and prognosis are located in the inva-
sion front (16–18). However, current RP for tumor sampling are 
not emphasizing enough the necessity of analyzing thoroughly 
this specific zone (9).
Urinary Bladder
Urothelial cell carcinomas of the urinary bladder are common 
neoplasms in Western countries. Over new 76,000 cases will 
occur in USA in 2016 (19). A relatively small number of UCC 
undergo radical cystectomy after TUR (20). As acknowledged 
by Chandra et  al. (21), many of the recommendations per-
formed in the last consensuses of bladder cancer were not 
supported by a strong evidence base. ITH has not yet been 
thoroughly analyzed in high-grade UCC, and the tumor inva-
sion front into the bladder wall, or beyond, has not received 
much attention for preferential sampling by pathologists (22, 
23). However, as it has been reported recently for renal cancer 
(7) and other neoplasms (24), the tumor periphery and the 
tumor invasion front may be important sites with distinct 
microenvironment and/or somatic mutations (17). Although 
a recent whole exome sequencing study with three metastatic 
UCCs reports low spatial genomic ITH in the primary tumors 
(25), these results need to be confirmed in larger series. 
Variations in grade and methylation status are, however, 
common findings in UCC, and necrosis, growth pattern 
(papillary vs flat), and histological subtyping are well-known 
classic features with impact on survival that deserve proper 
identification (26, 27).
stomach
Although declining in Western countries during the last dec-
ades, new 26,000 cases of GACs are expected in USA in 2016 
(19). The major responsible for the decrease of incidence are 
the successful treatment of Helicobacter pylori and changes in 
lifestyle (28). GAC is another paradigmatic example of highly 
heterogeneous neoplasm (29, 30). Most GACs are sporadic, 
but a minority of cases are familiar and hereditary taking 
part of several different clinical settings (31, 32). Lauren clas-
sification of GAC (intestinal, diffuse, and indeterminate types) 
is still in vogue among most pathologists worldwide (33). 
Recommendations for pathology reporting GAC include staging 
data and histological predictors of aggressiveness (34). Tumor 
budding, a change related to local epithelial-to-mesenchymal 
transition (35), is related with clinical aggressiveness, similar 
FigUre 1 | Practical implementation of multisite tumor sampling in a 
gastric adenocarcinoma (gAc). Two slices of a GAC after the application 
of multi-wheel rolling pasta cutter obtaining multiple tumor bars that include 
the full thickness of the tumor (including the front of tumor invasion) that fit six 
of them in the same cassette (the patient gave written informed consent for 
the use of this biological material for scientific purposes).
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to what happens for most carcinomas arising along the entire 
digestive tract and head and neck (18, 36).
Large Bowel
Colorectal adenocarcinoma is one of the most common human 
cancers in Western countries. Over new 95,000 cases will occur 
in USA in 2016 (19). High-quality pathology reporting of CRC 
includes staging data and histological predictors of aggressiveness 
(37). It is well known the importance of histological tumor grade/
differentiation, of invasion depth, and of the tumor distance from 
the radial margin in the rectum. Less appreciated, but equally 
important events are tumor budding (18), extramural venous 
invasion (38), and perineural invasion (39). These changes occur 
at the tumor invasive front. Molecular tumor characteristics 
(affected by genetics, epigenetics, stroma, local immune response, 
vascularization, and hypoxia characteristics) are also used to 
define prognostic categories (40). Finally, CRC was proven to 
be a molecularly complex and highly heterogeneous disease at 
inter- and intratumor levels (41).
A Msts sOLUtiON
Pathologists around the world every day face the same dilemma 
when making the sampling of large tumors: where to sample 
and when to stop sampling. Many tumors that are totally homo-
geneous by the naked eye might present in fact high levels of 
molecular ITH, what increases the pressure to pathologists when 
performing the sampling. Although there exist some classic rules 
in relation with tumor/non-tumor interface, necrosis, hemor-
rhage, tumor edges, etcetera, however, focusing on the tumor 
itself, pathologists are sampling tumors in a quasi-blind fashion 
following dogmatic rules or local customs and habits, and this 
situation is no longer acceptable.
The solution for ITH detection must be affordable and work-
able at the same time, thereby balancing scientific accuracy and 
cost. A total tumor sampling, when possible, is the ideal solu-
tion. However, many tumors are too large and cannot be totally 
sampled without collapsing the laboratory workflow. In these 
cases, pathologists must decide how large the sampling must 
be. Although (as far as we know) there is no official answer to 
this question at this time, we have recently proposed a method 
to increase the number of samples in CCRCC while keeping the 
same cost fixed (42). We showed [in silico analysis (10), method 
implementation (43), and clinical validation (11)] that a better 
alternative for tumor sampling is possible: MSTS.
Here, we have adapted our method to the topographic peculi-
arities of stomach, large bowel, and urinary bladder, respectively, 
and have performed a similar in silico approach to the problem 
with colon cancer as an example. On the one hand, the mod-
eling takes into account both microsatellite stable and unstable 
tumor categories in CRC. On the other hand, different densities 
of tumor budding, extramural venous invasion, and perineural 
invasion at the tumor front of invasion have also been considered 
in the analysis.
The goal of MSTS is the recruitment of many tumor samples 
for analysis, but the procedure must be adapted to specific tumor 
shape. Excavated and plaque-like neoplasms can be sampled 
with full-thickness bars of tumor tissue including the lower 
invasion front. Next, six to eight of these bars are placed in the 
same cassette for study (Figure 1). A thorough analysis of the 
invasion front into the wall seems mandatory in these tumors, 
not only for assessing ITH (histological or molecular) at any 
level in the vertical axis but also to discover tumor budding, and 
intravascular/perineural invasions, or any other morphologic 
feature with prognostic implications. Thick plateau-like and 
polypoid tumors can be sampled with a mixture of bars at the 
tumor invasion front and cubes at the rest, in a similar way we 
have previously proposed in CCRCC (10, 11). This way, MSTS is 
adapted to any possible situation, and many more tumor regions 
can be sampled without increasing laboratory costs (pathology 
laboratory costs are calculated by the number of paraffin blocks 
used for the analysis, where the higher the number of blocks, 
the higher the cost).
Since obtaining a large amount of these full-thickness tissue 
bars along several tumor slices may be perceived as too laborious 
by pathologists, we propose here the use of a multi-wheel rolling 
pasta cutter (or any similar device) (Figure 1) to get several bars 
in one step. Similarly, we proposed very recently a potato cutter 
grid for MSTS implementation in CCRCC (43).
Our accumulated experience with MSTS points to this 
method as the most affordable sampling strategy in large tumors 
to guarantee a proper ITH detection without increasing cost. It 
seems, however, that MSTS must be adapted to the tumor shape, 
on the one hand, and to the tumor topography, on the other hand. 
Tumors growing as 3D spheroids like those arising in the kidney, 
liver, lung, breast, and soft tissues, for example, are not confined 
by anatomical barriers and are well sampled with tissue cubes, as 
recently shown (11). However, tumors with more or less flattened 
shapes, arising in hollow viscera, are confined by well-defined 
anatomical barriers, namely, muscularis propria. In this context, 
MSTS must take into account the tumor orientation for sampling 
to get information at different levels of the wall. Obtaining tumor 
bars including (if possible) the whole tumor thickness is the best 
option for these cases.
FigUre 2 | A new divide-and-conquer (DAc) strategy outperforms rP 
in hollow viscera tumors, detecting better intratumor heterogeneity 
(itH) and equally well budding. (A) For low values of budding density, 
DAC detects more ITH than RP (red vs blue lines). DAC and RP performed 
equally well in detecting budding (magenta vs red lines). (B) Similar to panel 
(A), but intermediate values of budding density. (c) Similar to panel (A), but 
high values of budding density. (A–c) Percentage of either ITH or budding 
(B) detection (mean ± SE) as a function of the percentage of ITH density 
defining for each tumor. SE was calculated across N different repetitions of 
the same strategy and across M different tumors. Simulations parameters: 
L = 30 (side of 3 × L rectangle), H (number of sites with ITH) varying from 1 
to 80 (or equivalently the ITH density ρ varying from approximately 0 to 89%), 
B (number of sites with budding) varying from 1 to 30 (or equivalently the 
budding density σ varying from approximately 0 to 100%), N = 50 (repetitions 
number for the two RP and DAC strategies), and M = 15 (number of 
simulated tumors). For the two strategies, RP and DAC, the total number of 
blocks for each repetition was equal to Q, which as explained in our previous 
approach, was modeling the laboratory costs. Hereon, we chose Q = 9 for 
both DAC and RP. For DAC, the Q sites consisted in three different parallel 
tissue stripes chosen at random (i.e., occupying i = 1, i = 2, and i = 3 sites 
and three random j’s, from j = 1, …, L). For RP, we first chose a site J 
randomly between 2 and L − 1, and after the sites (i,J), (i,J + 1), and (i,J − 1) 
with i = 1, 2, and 3.
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IN SILICO MODeLiNg iN FAvOr OF Msts 
FOr HOLLOW viscerA tUMOrs
We extended here the modeling approach we performed in 
our previous paper (10), but now the tumor shape is assumed 
to be a rectangle of dimensions 3 × L. So, the ITH modeling is 
similar to the previous one (10) and is represented by the matrix 
(γ)ij ≡ {0,1} with i = 1, …, 3 (indicating rows) and j = 1, …, L 
(indicating column). The 0 value models homogeneity, while the 
1 value models the presence of ITH at tumor position (i,j). Tumor 
budding (extendible to extramural venous invasion or perineural 
invasion) is represented by a different matrix (θ)ij ≡ {0,1}, where 
the 0 and 1 values represent, respectively, absence or presence of 
budding in position (i,j).
Similar to our previous approach (10), two classes of ITH 
were modeled, random ITH (ranITH) and regional ITH 
(regITH). For both ranITH and regITH situations, ITH was 
simulated using an iterative method with h =  1, …,  H steps 
and where the initial condition was for all the cases γ =  0. 
At each step h, a 2D position (i,j) is chosen at random and a 
value of (γ)ij = 1 is assigned. After the H steps, the γ matrix is 
fixed and defines the tumor ITH configuration. The percent-
age of ITH density associated with a given tumor is defined as 
ρ ≡
×
×
H
L3
100  (c.f., x-axis in Figure 2).
For the ranITH situation, the matrix elements of γ were 
randomly generated at position (i,j), with no constraints for 
i and j, and this occurred for all the H steps. By contrast, for 
regITH, only at the first iteration (h =  1), the value of γ was 
assigned at position (i,j) with no constraints for i and j (using the 
same procedure as for ranITH), but for the following iterations 
(h ≥ 2), either the new chosen i or the new j was constrained 
to be necessarily a neighbor index of any of all the previously 
chosen i or j.
Budding was present only in tumor row of i = 1 (modeling the 
tumor invasion front). Budding was simulated using an iterative 
method with b = 1, …, B steps and where the initial condition 
was for all the cases θ =  0. At each step b, a random position 
j = 1, …, L was chosen and a value of (θ)1j = 1 was assigned. After 
the B steps, the θ matrix is fixed and defines the configuration 
of tumor budding. The percentage of budding density associated 
with a given tumor is defined as σ ≡ ×B
L
100.
For a given tumor, and after introducing fixed ITH and bud-
ding configurations defined by γ and θ, we repeated N times 
(and separately) two different strategies: routine protocol (RP, 
the one accepted in routine pathology) and our alternative, the 
DAC strategy. For each repetition and strategy, we calculated 
the number of successfully detected ITH and budding sites. 
Results were averaged across the N repetitions and also across 
M different tumors (each one with different ITH and budding 
configurations) (Figure 2).
tAKe-HOMe MessAges
Multisite tumor sampling is the best method for tumor sampling 
to detect ITH balancing high performance and sustainable cost. 
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MSTS must be adapted to tumor shape and tumor location for an 
optimal performance.
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